Mazdutide — Dual GLP-1/Glucagon Receptor Agonist
Mazdutide (IBI362) is a dual GLP-1 and glucagon receptor co-agonist in Phase 3 clinical investigation for obesity management and metabolic disease. Developed by Innovent Biologics, Mazdutide leverages synergistic receptor co-activation to amplify both appetite suppression (GLP-1) and fat mobilization/thermogenesis (glucagon), producing a more powerful metabolic effect than GLP-1 monotherapy.
Available Formats
- 5mg
- 10mg
Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials at 2–8°C.
Key Research Areas
⚡ Weight Loss Research
Phase 2 GLORY trial data demonstrates dose-dependent weight loss with Mazdutide reaching up to 14.5% body weight reduction over 24 weeks — among the highest reported for dual agonists at similar timepoints. Phase 3 trials are ongoing with expected further data.
🔥 Thermogenesis & Lipolysis
Glucagon receptor activation drives hepatic glucose production, free fatty acid oxidation, and thermogenesis — mechanisms absent in pure GLP-1 agonists. Combined, research models show preferential visceral fat reduction.
🩸 Glycaemic Control
GLP-1 component drives glucose-dependent insulin secretion with low hypoglycaemia risk. Research models show meaningful HbA1c reduction in T2D and pre-diabetes models.
🧬 NASH & Fatty Liver Research
Glucagon receptor activity in hepatocytes makes Mazdutide a research compound of interest for NASH, with pre-clinical and early clinical data suggesting reductions in hepatic fat content.
Why Choose EhBuddy?
- ✅ Verified Purity — Third-party tested for identity and potency
- ✅ Fast Canadian Shipping — Discreet packaging, shipped from Canada
- ✅ Research-Grade Quality — Strict manufacturing quality standards
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
Reviews
There are no reviews yet.